We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This guidance provides information on comparator products used in studies supporting abridged marketing authorisation applications
Advice to give pregnant women on infections that can be transmitted via contact with animals that are or have recently given birth.
How to register your medical devices with the Medicines and Healthcare products Regulatory Agency (MHRA) for the markets in Great Britain and Northern Ireland
Advice and guidance on the health needs of migrant patients from Argentina for healthcare practitioners.
The MHRA has authorised cabotegravir as 30 mg tablets and as a 600 mg long-acting injection administered every two months
A patient alert card is being introduced for men taking finasteride to help raise awareness of the risk of psychiatric side effects and sexual dysfunction, including the potential for sexual dysfunction to persist after treatment has stopped. Healthcare professionals are...
Guidance to help organisations choose a monitoring approach for stack emissions to air that meets Environment Agency and MCERTS requirements (formerly part of M2).
Information about the EU Regulations and their implementation in Northern Ireland
This document explains the Prostate Cancer Risk Management Programme (PCRMP), PSA testing and evidence against a national screening programme.
Find out about terrorist threat levels, national measures against terrorism and how to report suspect activity
Explains testing from 1 April 2024 onwards and sets out the purpose of ongoing testing, who will be eligible to access testing and when tests should be used.
Healthcare professionals prescribing montelukast should be alert to the risk of neuropsychiatric reactions in all patients including children and adolescents. Reported neuropsychiatric reactions include sleep disorders, hallucinations, anxiety and depression, as well as changes in behaviour and mood. Healthcare professionals...
These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.
Guidance on the collection and reporting of data for CTAD, the surveillance system for all chlamydia tests done in England.
How catch limits are set and how to get involved in setting them. This includes current catch limits and closed fishing areas.
This playbook explains how we use social media at GDS. In it, we share our best practice, what we've learned and what we're planning to do.
Business potential of producing crops for non-food markets, how and where to grow them and details of organisations providing grants.
LLWR newsletters
FCDO travel advice for Guatemala. Includes safety and security, insurance, entry requirements and legal differences.
Further measures to be introduced to ensure patients who are prescribed montelukast for the treatment of asthma are informed of the risk of neuropsychiatric reactions
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.